Neuphoria Therapeutics (NEUP) Change in Account Payables (2023 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Change in Account Payables of $106476.0 for Q1 2026, up 113.56% year-over-year from $49858.1 in Q1 2025, and up 112.53% quarter-over-quarter from -$850019.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) Change in Account Payables (2023 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Change in Account Payables for 4 consecutive years, with $106476.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 113.56% year-over-year to $106476.0; the TTM figure through Mar 2026 stood at $53479.0 (down 67.59% YoY), while the FY2025 annual figure was -$917663.0, down 214.08% from the prior year.
- Change in Account Payables climbed to $106476.0 in Q1 2026 per NEUP's latest filing, from -$850019.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.7 million in Q2 2024 and bottomed at -$917668.0 in Q3 2024.
- Historically, Change in Account Payables has averaged -$58225.1 across 4 years, with a median of $106476.0 in 2026.
- On a YoY basis, Change in Account Payables climbed as much as 123.58% in 2025 and fell as far as 515.31% in 2025.
- Neuphoria Therapeutics' Change in Account Payables stood at -$874005.0 in 2023, then jumped by 123.42% to $204673.0 in 2024, then tumbled by 515.31% to -$850019.0 in 2025, then surged by 112.53% to $106476.0 in 2026.
- Business Quant data shows NEUP's Change in Account Payables at $106476.0 in Q1 2026, -$850019.0 in Q4 2025, and $216359.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Neuphoria Therapeutics | 21.28 Mn | 1.84 Mn | - | 106,476.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 106,476.00 |
| Mar 31, 2026 | 106,476.00 |
| Dec 31, 2025 | -850,019.00 |
| Dec 31, 2025 | -850,019.00 |
| Sep 30, 2025 | 216,359.00 |
| Sep 30, 2025 | 216,359.00 |
| Jun 30, 2025 | 580,663.00 |
| Jun 30, 2025 | 580,663.00 |
| Mar 31, 2025 | -785,331.00 |
| Mar 31, 2025 | -785,331.00 |
| Dec 31, 2024 | 204,673.00 |
| Dec 31, 2024 | 204,673.00 |
| Sep 30, 2024 | -917,668.00 |
| Sep 30, 2024 | -917,668.00 |
| Jun 30, 2024 | 1.66 Mn |
| Jun 30, 2024 | 1.66 Mn |
| Mar 31, 2024 | -865,560.00 |
| Mar 31, 2024 | -865,560.00 |
| Dec 31, 2023 | -874,005.00 |
| Dec 31, 2023 | -874,005.00 |